文献速递神经肿瘤

低级别胶质瘤中CD34微血管密度与5-氨基乙酰丙酸荧光及患者预后的相关性:三家专科中心的多中心研究

CD34 microvascularity in low-grade glioma: correlation with 5-aminolevulinic acid fluorescence and patient prognosis in a multicenter study at three specialized centers.
PubMed 文献 · J Neurosurg · 2022-09-16

该多中心回顾性研究纳入86例异柠檬酸脱氢酶突变型WHO II级低级别胶质瘤患者,分析术中5-ALA荧光与CD34微血管密度的相关性及预后价值。结果显示可见荧光仅见于13例(15%),CD34半定量评分与荧光显著相关(p=0.049),定量微血管密度>10个血管/mm²是不良无进展生存、无恶性转化生存和总生存的预后标志。

要点

  • 86例低级别胶质瘤中仅13例(15%)术中可见5-ALA荧光。
  • CD34半定量评分与术中荧光显著相关(p=0.049),荧光组定量微血管密度更高(p=0.03)。
  • 微血管簇是不良无进展生存(p=0.01)和无恶性转化生存(p=0.006)的预后标志,但与总生存无关(p=0.28)。

核心结论

  • CD34微血管密度与低级别胶质瘤术中5-ALA荧光及患者结局相关,可见荧光可能提示CD34微血管密度增加,可作为术中即可获得的早期不良预后标志。

研究设计与样本

  • 回顾性研究,纳入3家专科中心经组织病理学确诊的异柠檬酸脱氢酶突变型WHO II级低级别胶质瘤患者86例,术前接受5-ALA。

主要发现

  • 86例低级别胶质瘤中,术中可见荧光13例(15%)。
  • CD34半定量评分与术中荧光显著相关(p=0.049),荧光组定量CD34微血管密度显著更高(p=0.03)。
  • CD34半定量评分与定量CD34微血管密度强相关(p<0.001)。
  • 中位随访5.4±2.6年,半定量分析中的微血管簇是不良无进展生存(p=0.01)和无恶性转化生存(p=0.006)的预后标志,但与总生存无关(p=0.28)。
  • 定量CD34微血管密度>10个血管/mm²是不良无进展生存(p=0.01)、无恶性转化生存(p=0.008)和总生存(p=0.049)的预后标志。

关键数值与推荐

  • CD34半定量评分与术中荧光相关(p=0.049)。
  • 荧光组定量CD34微血管密度显著高于无荧光组(p=0.03)。
  • 微血管簇预测不良无进展生存(p=0.01)和无恶性转化生存(p=0.006),与总生存无关(p=0.28)。
  • 定量CD34微血管密度>10个血管/mm²预测不良无进展生存(p=0.01)、无恶性转化生存(p=0.008)和总生存(p=0.049)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Early markers are urgently needed in low-grade glioma (LGG) evaluation to rapidly estimate the individual patient's prognosis and to determine the optimal postoperative management. Generally, visible 5-aminolevulinic acid (5-ALA) fluorescence is present in only a few LGGs. Recently, the authors identified visible 5-ALA fluorescence as a powerful intraoperative marker for unfavorable outcome in LGG treatment. However, its precise histopathological correlate is unclear. Neoangiogenesis represents a crucial event in tumor evolution, and CD34 is an established marker for vascular endothelial progenitors potentially indicating tumor progression. The aim of this study was thus to correlate 5-ALA fluorescence and CD34 microvascularity as well as to investigate the prognostic value of CD34 in a large series of LGGs. METHODS: In this retrospective study including 3 specialized centers, patients with histopathologically confirmed isocitrate dehydrogenase-mutated LGGs (WHO grade II) receiving 5-ALA prior to resection were included. During surgery, the presence of visible fluorescence was analyzed and one representative tumor sample from the area with the maximum fluorescence effect (tumor with focal fluorescence or nonfluorescing tumor) was selected for each LGG. All fluorescing or nonfluorescing tumor samples were stained for CD34 and semiquantitatively analyzed for microvascular proliferation patterns (physiological vessels, branching capillaries, or microvessel clusters) as well as automatically quantified for CD34 microvessel density (MVD) by standardized histomorphometry software. These semiquantitative/quantitative CD34 data were correlated to the fluorescence status and patient outcome including progression-free survival (PFS), malignant transformation-free survival (MTFS), and overall survival (OS). RESULTS: In a total of 86 LGGs, visible fluorescence was found during surgery in 13 (15%) cases. First, the semiquantitative CD34 score significantly correlated with intraoperative fluorescence (p = 0.049). Accordingly, the quantitative CD34 MVD was significantly higher in tumors showing fluorescence (p = 0.03). Altogether, the semiquantitative CD34 score showed a strong correlation with quantitative CD34 MVD (p < 0.001). At a mean follow-up of 5.4 ± 2.6 years, microvessel clusters in semiquantitative analysis were a prognostic marker for poor PFS (p = 0.01) and MTFS (p = 0.006), but not OS (p = 0.28). Finally, quantitative CD34 MVD > 10 vessels/mm2 was a prognostic marker for poor PFS (p = 0.01), MTFS (p = 0.008), and OS (p = 0.049). CONCLUSIONS: The data indicate that CD34 microvascularity is associated with intraoperative 5-ALA fluorescence and outcomes in patients with LGG. Thus, visible fluorescence in LGGs might indicate increased CD34 microvascularity, serving as an early prognostic marker for unfavorable patient outcome that is already available during surgery.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Hosmann A, Jaber M, Roetzer-Pejrimovsky T, et al. CD34 microvascularity in low-grade glioma: correlation with 5-aminolevulinic acid fluorescence and patient prognosis in a multicenter study at three specialized centers. J Neurosurg. 2022. PMID: 36115057. doi:10.3171/2022.7.JNS22921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。